Merck & Co. (MRK)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$128.87+1.65%
Close 2026-07-07 · 1-day change
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading MRK? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track MRK free→Merck grows revenue about 4.3% next year. Profit per share is guided near $5.10. New cancer drug approvals boost future sales. The company raised revenue and profit forecasts recently.
Legal investigations in China could hurt Merck's reputation. This may slow growth. Profit guidance is mixed despite recent raises.
The price is about 27% above our fair value near $101. Analysts expect 4% revenue growth. Our fair value is below the Street's median of $146.
Breaks if: EPS falls below $5.04 in FY26
Raise the expected non-GAAP EPS range for the fiscal year 2026.
Stated in 2 of last 2 quarters. EPS guidance was raised to $5.04-$5.16 for 2026. Despite a GAAP loss per share of $1.72 in 2026-Q1, the company maintains its raised EPS guidance, indicating confidence in future earnings potential.
Breaks if: Material penalties or operational disruptions from China investigations
Breaks if: No significant oncology approvals or pipeline advances in 12 months
Focus on advancing the oncology pipeline with significant regulatory and clinical milestones.
Breaks if: Revenue falls below $65.8 billion in FY26
Increase the revenue guidance for the fiscal year 2026.
Stated in 2 of last 2 quarters. Revenue guidance was raised to $65.8B-$67.0B for 2026. Revenue for 2026-Q1 was $16.3 billion, a 5% increase from 2025-Q1. The trajectory is on track with the raised guidance.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Merck narrows and raises expected non-GAAP EPS range to be between $5.04 and $5.16.”
“Expects non-GAAP EPS to be between $5.00 and $5.15.”
“Merck now expects sales to be between $65.8 billion and $67.0 billion.”
“Anticipates worldwide sales to be between $65.5 billion and $67.0 billion.”